{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T17:20:01Z","timestamp":1790443201598,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,19]]},"DOI":"10.7759\/cureus.14006","type":"journal-article","created":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T01:30:19Z","timestamp":1616203819000},"source":"Crossref","is-referenced-by-count":9,"title":["Diagnosis and Management of Gastrointestinal Neuroendocrine Tumors: A Comprehensive Literature Review"],"prefix":"10.7759","author":[{"given":"Omid","family":"Yazdanpanah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarvani","family":"Surapaneni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Layla","family":"Shanah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohaip","family":"Kabashneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2017.09.002","article-title":"Nothing but NET: a review of neuroendocrine tumors and carcinomas","volume":"19","author":"Oronsky B","year":"2017","unstructured":"Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing but NET: a review of neuroendocrine tumors and carcinomas. Neoplasia. 2017, 19:991-1002. 10.1016\/j.neo.2017.09.002","journal-title":"Neoplasia"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1210\/er.2003-0014","article-title":"The diagnosis and medical management of advanced neuroendocrine tumors","volume":"25","author":"Kaltsas GA","year":"2004","unstructured":"Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev. 2004, 25:458-511. 10.1210\/er.2003-0014","journal-title":"Endocr Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-018-0110-y","article-title":"A common classification framework for neuroendocrine neoplasms: An international agency for research on cancer (IARC) and world health organization (WHO) expert consensus proposal","volume":"31","author":"Rindi G","year":"2018","unstructured":"Rindi G, Klimstra DS, Abedi-Ardekani B, et al.. A common classification framework for neuroendocrine neoplasms: An international agency for research on cancer (IARC) and world health organization (WHO) expert consensus proposal. Mod Pathol. 2018, 31:1770-1786. 10.1038\/s41379-018-0110-y","journal-title":"Mod Pathol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1210\/er.2018-00160","article-title":"Genetics and epigenetics of gastroenteropancreatic neuroendocrine neoplasms","volume":"40","author":"Mafficini A","year":"2019","unstructured":"Mafficini A, Scarpa A. Genetics and epigenetics of gastroenteropancreatic neuroendocrine neoplasms. Endocr Rev. 2019, 40:506-536. 10.1210\/er.2018-00160","journal-title":"Endocr Rev"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1159\/000080731","article-title":"Epidemiology of neuroendocrine tumours","volume":"80","author":"Taal BG","year":"2004","unstructured":"Taal BG, Visser O. Epidemiology of neuroendocrine tumours. Neuroendocrinology. 2004, 80:3-7. 10.1159\/000080731","journal-title":"Neuroendocrinology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the united states","volume":"3","author":"Dasari A","year":"2017","unstructured":"Dasari A, Shen C, Halperin D, et al.. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the united states. JAMA Oncol. 2017, 3:1335-1342. 10.1001\/jamaoncol.2017.0589","journal-title":"JAMA Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-12-0024","article-title":"Neuroendocrine tumor disease: an evolving landscape","volume":"19","author":"Frilling A","year":"2012","unstructured":"Frilling A, Akerstr\u00f6m G, Falconi M, Pavel M, Ramos J, Kidd M, Modlin IM. Neuroendocrine tumor disease: an evolving landscape. Endocr Relat Cancer. 2012, 19:163-10. 10.1530\/ERC-12-0024","journal-title":"Endocr Relat Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21493","article-title":"Gastroenteropancreatic neuroendocrine tumors","volume":"68","author":"Cives M","year":"2018","unstructured":"Cives M, Strosberg JR. Gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin. 2018, 68:471-487. 10.3322\/caac.21493","journal-title":"CA Cancer J Clin"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2821","article-title":"Somatic mutation of CDKN1B in small intestine neuroendocrine tumors","volume":"45","author":"Francis JM","year":"2013","unstructured":"Francis JM, Kiezun A, Ramos AH, et al.. Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nat Genet. 2013, 45:1483-1486. 10.1038\/ng.2821","journal-title":"Nat Genet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1126\/science.1200609","article-title":"DAXX\/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors","volume":"331","author":"Jiao Y","year":"2011","unstructured":"Jiao Y, Shi C, Edil BH, et al.. DAXX\/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011, 331:1199-1203. 10.1126\/science.1200609","journal-title":"Science"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3182417d36","article-title":"Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors","volume":"36","author":"Yachida S","year":"2012","unstructured":"Yachida S, Vakiani E, White CM, et al.. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol. 2012, 36:173-184. 10.1097\/PAS.0b013e3182417d36","journal-title":"Am J Surg Pathol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-007-0450-3","article-title":"Hereditary neuroendocrine tumors of the gastroenteropancreatic system","volume":"451","author":"Anlauf M","year":"2007","unstructured":"Anlauf M, Garbrecht N, Bauersfeld J, et al.. Hereditary neuroendocrine tumors of the gastroenteropancreatic system. Virchows Arch. 2007, 451:S29-38. 10.1007\/s00428-007-0450-3","journal-title":"Virchows Arch"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.03.038","article-title":"Current status of gastrointestinal carcinoids","volume":"128","author":"Modlin IM","year":"2005","unstructured":"Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current status of gastrointestinal carcinoids. Gastroenterology. 2005, 128:1717-1751. 10.1053\/j.gastro.2005.03.038","journal-title":"Gastroenterology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2017.04.004","article-title":"Biochemical testing in neuroendocrine tumors","volume":"46","author":"Aluri V","year":"2017","unstructured":"Aluri V, Dillon JS. Biochemical testing in neuroendocrine tumors. Endocrinol Metab Clin North Am. 2017, 46:669-677. 10.1016\/j.ecl.2017.04.004","journal-title":"Endocrinol Metab Clin North Am"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)02286-7","article-title":"Carcinoid tumour","volume":"352","author":"Caplin ME","year":"1998","unstructured":"Caplin ME, Buscombe JR, Hilson AJ, Jones AL, Watkinson AF, Burroughs AK. Carcinoid tumour. Lancet. 1998, 352:799-805. 10.1016\/S0140-6736(98)02286-7","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.07.057","article-title":"The flushing patient: Differential diagnosis, workup, and treatment","volume":"55","author":"Izikson L","year":"2006","unstructured":"Izikson L, English JC 3rd, Zirwas MJ. The flushing patient: Differential diagnosis, workup, and treatment. J Am Acad Dermatol. 2006, 55:193-208. 10.1016\/j.jaad.2005.07.057","journal-title":"J Am Acad Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199310073291503","article-title":"Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea","volume":"329","author":"von der Ohe MR","year":"1993","unstructured":"von der Ohe MR, Camilleri M, Kvols LK, Thomforde GM. Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea. N Engl J Med. 1993, 329:1073-1078. 10.1056\/NEJM199310073291503","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1159\/000507847","article-title":"Carcinoid heart disease: Pathophysiology, pathology, clinical manifestations, and management","volume":"146","author":"Jin C","year":"2020","unstructured":"Jin C, Sharma AN, Thevakumar B, et al.. Carcinoid heart disease: Pathophysiology, pathology, clinical manifestations, and management. Cardiology. 2020, 146:65-73. 10.1159\/000507847","journal-title":"Cardiology"},{"key":"ref19","article-title":"Carcinoid Syndrome","author":"Pandit S","year":"2020","unstructured":"Pandit S, Annamaraju P, Bhusal K. Carcinoid Syndrome. StatPearls Publishing LLC, Treasure Island; 2020."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.10333","article-title":"Clinical signs of fibrosis in small intestinal neuroendocrine tumours","volume":"104","author":"Daskalakis K","year":"2017","unstructured":"Daskalakis K, Karakatsanis A, St\u00e5lberg P, Norl\u00e9n O, Hellman P. Clinical signs of fibrosis in small intestinal neuroendocrine tumours. Br J Surg. 2017, 104:69-75. 10.1002\/bjs.10333","journal-title":"Br J Surg"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(76)80460-X","article-title":"Studies of tryptophan and albumin metabolism in a patient with carcinoid syndrome, pellagra, and hypoproteinemia","volume":"71","author":"Swain CP","year":"1976","unstructured":"Swain CP, Tavill AS, Neale G. Studies of tryptophan and albumin metabolism in a patient with carcinoid syndrome, pellagra, and hypoproteinemia. Gastroenterology. 1976, 71:484-489. 10.1016\/S0016-5085(76)80460-X","journal-title":"Gastroenterology"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2005.06.002","article-title":"Endocrine tumours of the pancreas","volume":"19","author":"\u00d6berg K","year":"2005","unstructured":"\u00d6berg K, Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol. 2005, 19:753-781. 10.1016\/j.bpg.2005.06.002","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1159\/000051853","article-title":"Tumor markers in neuroendocrine tumors","volume":"62","author":"Eriksson B","year":"2000","unstructured":"Eriksson B, \u00d6berg K, Stridsberg M. Tumor markers in neuroendocrine tumors. Digestion. 2000, 62:33-38. 10.1159\/000051853","journal-title":"Digestion"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.14701\/ahbps.2018.22.1.66","article-title":"Nonfunctioning neuroendocrine pancreatic tumors: Our experience and management","volume":"16","author":"Nomura N","year":"2009","unstructured":"Nomura N, Fujii T, Kanazumi N, et al.. Nonfunctioning neuroendocrine pancreatic tumors: Our experience and management. J Hepatobiliary Pancreat Surg. 2009, 16:639-647. 10.14701\/ahbps.2018.22.1.66","journal-title":"J Hepatobiliary Pancreat Surg"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1159\/000225948","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine tumors: biochemical markers","volume":"90","author":"O'Toole D","year":"2009","unstructured":"O'Toole D, Grossman A, Gross D, et al.. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: biochemical markers. Neuroendocrinology. 2009, 90:194-202. 10.1159\/000225948","journal-title":"Neuroendocrinology"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-010-1006-3","article-title":"Chromogranin A - biological function and clinical utility in neuro endocrine tumor disease","volume":"17","author":"Modlin IM","year":"2010","unstructured":"Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M. Chromogranin A - biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol. 2010, 17:2427-2443. 10.1245\/s10434-010-1006-3","journal-title":"Ann Surg Oncol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.5301\/JBM.2011.8327","article-title":"Chromogranin A measurement in metastatic well-differentiated gastroenteropancreatic neuroendocrine carcinoma: screening for false positives and a prospective follow-up study","volume":"26","author":"Vezzosi D","year":"2011","unstructured":"Vezzosi D, Walter T, Laplanche A, et al.. Chromogranin A measurement in metastatic well-differentiated gastroenteropancreatic neuroendocrine carcinoma: screening for false positives and a prospective follow-up study. Int J Biol Markers. 2011, 26:94-101. 10.5301\/JBM.2011.8327","journal-title":"Int J Biol Markers"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1159\/000321535","article-title":"Effect of proton-pump inhibitor therapy on serum chromogranin a level","volume":"84","author":"Pregun I","year":"2011","unstructured":"Pregun I, Hersz\u00e9nyi L, Juh\u00e1sz M, et al.. Effect of proton-pump inhibitor therapy on serum chromogranin a level. Digestion. 2011, 84:22-28. 10.1159\/000321535","journal-title":"Digestion"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1770337","article-title":"A comparison between three commercial kits for chromogranin A measurements","volume":"177","author":"Stridsberg M","year":"2003","unstructured":"Stridsberg M, Eriksson B, Oberg K, Janson ET. A comparison between three commercial kits for chromogranin A measurements. J Endocrinol. 2003, 177:337-341. 10.1677\/joe.0.1770337","journal-title":"J Endocrinol"},{"key":"ref30","article-title":"Single photon emission computed tomography procedure improves accuracy of somatostatin receptor scintigraphy in gastro-entero pancreatic tumours","volume":"31","author":"Schillaci O","year":"1999","unstructured":"Schillaci O, Corleto VD, Annibale B, Scopinaro F, Delle Fave G. Single photon emission computed tomography procedure improves accuracy of somatostatin receptor scintigraphy in gastro-entero pancreatic tumours. Ital J Gastroenterol Hepatol. 1999, 31:186-189.","journal-title":"Ital J Gastroenterol Hepatol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2003.01885.x","article-title":"SPECT\/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours","volume":"59","author":"Krausz Y","year":"2003","unstructured":"Krausz Y, Keidar Z, Kogan I, et al.. SPECT\/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours. Clin Endocrinol (Oxf). 2003, 59:565-573. 10.1046\/j.1365-2265.2003.01885.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.0987","article-title":"Prospective study of 68Ga-DOTATATE positron emission tomography\/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites","volume":"34","author":"Sadowski SM","year":"2016","unstructured":"Sadowski SM, Neychev V, Millo C, et al.. Prospective study of 68Ga-DOTATATE positron emission tomography\/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites. J Clin Oncol. 2016, 34:588-596. 10.1200\/JCO.2015.64.0987","journal-title":"J Clin Oncol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.202275","article-title":"Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors","volume":"59","author":"Hope TA","year":"2018","unstructured":"Hope TA, Bergsland EK, Bozkurt MF, et al.. Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors. J Nucl Med. 2018, 59:66-74. 10.2967\/jnumed.117.202275","journal-title":"J Nucl Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1159\/000464292","article-title":"ENETS consensus guidelines for standard of care in neuroendocrine tumours: Surgery for small intestinal and pancreatic neuroendocrine tumours","volume":"105","author":"Partelli S","year":"2017","unstructured":"Partelli S, Bartsch DK, Capdevila J, et al.. ENETS consensus guidelines for standard of care in neuroendocrine tumours: Surgery for small intestinal and pancreatic neuroendocrine tumours. Neuroendocrinology. 2017, 105:255-265. 10.1159\/000464292","journal-title":"Neuroendocrinology"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1159\/000343801","article-title":"Current size criteria for the management of neuroendocrine tumors of the appendix: are they valid? clinical experience and review of the literature","volume":"98","author":"Grozinsky-Glasberg S","year":"2013","unstructured":"Grozinsky-Glasberg S, Alexandraki KI, Barak D, Doviner V, Reissman P, Kaltsas GA, Gross DJ. Current size criteria for the management of neuroendocrine tumors of the appendix: are they valid? clinical experience and review of the literature. Neuroendocrinology. 2013, 98:31-37. 10.1159\/000343801","journal-title":"Neuroendocrinology"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1159\/000443166","article-title":"ENETS consensus guidelines update for colorectal neuroendocrine neoplasms","volume":"103","author":"Ramage JK","year":"2016","unstructured":"Ramage JK, De Herder WW, Delle Fave G, et al.. ENETS consensus guidelines update for colorectal neuroendocrine neoplasms. Neuroendocrinology. 2016, 103:139-143. 10.1159\/000443166","journal-title":"Neuroendocrinology"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1159\/000443167","article-title":"ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site","volume":"103","author":"Pavel M","year":"2016","unstructured":"Pavel M, O'Toole D, Costa F, et al.. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016, 103:172-185. 10.1159\/000443167","journal-title":"Neuroendocrinology"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1159\/000486096","article-title":"The evolution of neuroendocrine tumor treatment reflected by ENETS guidelines","volume":"106","author":"Zandee WT","year":"2018","unstructured":"Zandee WT, de Herder WW. The evolution of neuroendocrine tumor treatment reflected by ENETS guidelines. Neuroendocrinology. 2018, 106:357-365. 10.1159\/000486096","journal-title":"Neuroendocrinology"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group","volume":"27","author":"Rinke A","year":"2009","unstructured":"Rinke A, M\u00fcller HH, Schade-Brittinger C, et al.. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol. 2009, 27:4656-4663. 10.1200\/JCO.2009.22.8510","journal-title":"J Clin Oncol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1409757","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin ME","year":"2014","unstructured":"Caplin ME, Pavel M, Ruszniewski P. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014, 371:1556-1557. 10.1056\/NEJMc1409757","journal-title":"N Engl J Med"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.2780","article-title":"Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome","volume":"35","author":"Kulke MH","year":"2017","unstructured":"Kulke MH, H\u00f6rsch D, Caplin ME, et al.. Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome. Journal of clinical oncology. 2017, 35:14-23. 10.1200\/JCO.2016.69.2780","journal-title":"Journal of clinical oncology"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of (177)lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg J","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, et al.. Phase 3 trial of (177)lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017, 376:125-135. 10.1056\/NEJMoa1607427","journal-title":"N Engl J Med"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao JC","year":"2016","unstructured":"Yao JC, Fazio N, Singh S, et al.. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016, 387:968-977. 10.1016\/S0140-6736(15)00817-X","journal-title":"Lancet"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond E","year":"2011","unstructured":"Raymond E, Dahan L, Raoul JL, et al.. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011, 364:501-513. 10.1056\/NEJMoa1003825","journal-title":"N Engl J Med"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1159\/000443172","article-title":"ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas","volume":"103","author":"Garcia-Carbonero R","year":"2016","unstructured":"Garcia-Carbonero R, Sorbye H, Baudin E, et al.. ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology. 2016, 103:186-194. 10.1159\/000443172","journal-title":"Neuroendocrinology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/54110-diagnosis-and-management-of-gastrointestinal-neuroendocrine-tumors-a-comprehensive-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:25:29Z","timestamp":1707506729000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/54110-diagnosis-and-management-of-gastrointestinal-neuroendocrine-tumors-a-comprehensive-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,19]]},"references-count":45,"URL":"https:\/\/doi.org\/10.7759\/cureus.14006","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3,19]]}}}